secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001493152-25-023629
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)
--------------------------------------------------------------------------------

- Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.
- Income from operations $8.2M, up $4.7M or 136% YoY.
- Growth driven by lisdexamfetamine product launches and strong Elite label product lines.
- Conference call scheduled for Monday, Nov 17, 2025 at 11:30 AM EST.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/0001493152-25-023629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315225023629/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-023629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer